Shares of CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) have been given a consensus recommendation of "Buy" by the eight analysts that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $32.1429.
Separately, BTIG Research assumed coverage on CeriBell in a research report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price target for the company.
Check Out Our Latest Analysis on CBLL
CeriBell Price Performance
Shares of CBLL stock traded up $0.33 on Thursday, reaching $12.91. The company's stock had a trading volume of 629,190 shares, compared to its average volume of 289,622. The stock's fifty day simple moving average is $16.70 and its 200-day simple moving average is $18.51. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The company has a market capitalization of $473.28 million and a price-to-earnings ratio of -4.32. The company has a current ratio of 13.31, a quick ratio of 16.81 and a debt-to-equity ratio of 0.11.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The business had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.52 million. Analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.
Insider Transactions at CeriBell
In other news, Director Rebecca B. Robertson sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $17.14, for a total transaction of $342,800.00. Following the transaction, the director owned 28,675 shares of the company's stock, valued at approximately $491,489.50. This represents a 41.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Xingjuan Chao sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.00, for a total value of $425,000.00. Following the sale, the chief executive officer directly owned 776,022 shares of the company's stock, valued at $13,192,374. This represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 113,633 shares of company stock valued at $1,965,261. 20.10% of the stock is owned by corporate insiders.
Institutional Trading of CeriBell
A number of hedge funds and other institutional investors have recently bought and sold shares of CBLL. FMR LLC purchased a new stake in shares of CeriBell in the fourth quarter valued at approximately $128,120,000. TPG GP A LLC bought a new stake in CeriBell during the 4th quarter valued at $102,677,000. Red Tree Management LLC purchased a new stake in shares of CeriBell in the 4th quarter worth $57,083,000. Yu Fan bought a new position in shares of CeriBell during the 4th quarter worth $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in shares of CeriBell during the fourth quarter valued at $28,160,000.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access